Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSD UCSF
Dates
study started
completion around

Description

Summary

This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread to nearby tissue or lymph nodes (locally advanced), that cannot be removed by surgery (unresectable), or that has spread from where it first started (primary site) to other places in the body (metastatic). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. It is not known whether giving olaparib with or without atezolizumab will work better in patients with non-HER2-positive breast cancer.

Official Title

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Details

Keywords

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Carcinoma, Breast Neoplasms, Atezolizumab, Olaparib, Poly(ADP-ribose) Polymerase Inhibitors, Monoclonal Antibodies, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, X-Ray Imaging, olaparib, atezolizumab

Eligibility

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • UC San Diego Medical Center - Hillcrest
    San Diego California 92103 United States
  • UCSF Medical Center-Mount Zion
    San Francisco California 94115 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
Links
Related Info
ID
NCT02849496
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 81 study participants
Last Updated